PanagiotisKonstantinopoulosMDPhD

Gynecologic Cancer, Hematologic Oncology

Director Center for BRCA and Related Genes, Associate Professor of Medicine, Harvard Medical School, Director Translational Research, Gynecologic Oncology Program, Dana-Farber Cancer Institute

Join to view full profile

Dr. Konstantinopoulos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Konstantinopoulos' full profile

Already have an account?

Office
330 Brookline Ave
# Beth
Boston, MA 02215
Phone+1 617-667-2131

Education & Training

Harvard - MIT Health Sciences and TechnologyMMSc, Clinical Investigation, 2008 - 2010
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
SUNY Upstate Medical UniversityResidency, Internal Medicine, 2002 - 2005
University of Patras School of MedicineClass of 1997

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2005 - 2025
NH State Medical License 2023 - 2025

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer Start of enrollment: 2009 Mar 01
Terminated
Phase 2
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Start of enrollment: 2011 Mar 01
Completed
Phase 2
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Start of enrollment: 2011 Mar 01
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Start of enrollment: 2016 Mar 01
Withdrawn
Phase 1
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Start of enrollment: 2017 May 19
Completed
Phase 1
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer Start of enrollment: 2016 Nov 14
Active, not recruiting
Phase 2
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer Start of enrollment: 2018 Dec 24
Recruiting
Phase 2
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) Start of enrollment: 2020 Jan 02
Active, not recruiting
Phase 2
NeoVax With Nivolumab in Patients With Ovarian Cancer Start of enrollment: 2020 Nov 20
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

443 citations
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D'Andrea
Cancer Discovery. 2017-06-19
274 citations
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J. Hill, Brennan Decker, Emma A. Roberts, Neil S. Horowitz, Michael G. Muto
Cancer Discovery. 2018-09-13
38 citations
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
I-M Launonen, N Lyytikäinen, J Casado, E A Anttila, A Szabó
Nature Communications. 2022-02-11

Lectures

Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutate...
2019 ASCO Annual Meeting - 6/1/2019
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian ca...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

DYNLL1 Binds to MRE11 to Limit DNA End Resection in BRCA1-Deficient Cells
Panagiotis Konstantinopoulos, MD, Nature
https://www.doximity.com/articles/804b7938-38f7-46ed-bc4f-f3b8235a8ea6
UpToDate, Wolters Kluwer Health - 2012-12-13

Press Mentions

New Class of Cancer Drug Halts Tumor Growth in Early Human TrialsJune 23rd, 2020
New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP ComboMarch 19th, 2020
Avelumab Active in Mismatch Repair-Deficient Endometrial CancerOctober 3rd, 2019
Join now to see all